No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Why Jilin Jian Yisheng Pharmaceutical's (SZSE:002566) Shaky Earnings Are Just The Beginning Of Its Problems
Yisheng Pharmaceutical: Report for the third quarter of 2024
jilin jian yisheng pharmaceutical (002566.SZ): The net income in the first three quarters was 35.8648 million yuan, a decrease of 38.66% year-on-year.
Yisheng Pharmaceutical (002566.SZ) announced its third quarter report on October 25th. In the first three quarters of 2024, the company achieved a revenue of 0.506 billion yuan, a decrease of 22.36% year-on-year; net income attributable to the shareholders of the listed company was 35.8648 million yuan, a decrease of 38.66% year-on-year; net income after deducting non-recurring gains and losses was 20.1981 million yuan, a decrease of 54.55% year-on-year; basic earnings per share were 0.1084 yuan per share.
Jilin Jian Yisheng Pharmaceutical (002566.SZ) released its performance for the first three quarters, with net income of 35.8648 million yuan, a year-on-year decrease of 38.66%.
Jilin Jian Yisheng Pharmaceutical (002566.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved revenue...
Jilin Jian Yisheng Pharmaceutical: Half-year report for the year 2024.
Some Confidence Is Lacking In Jilin Jian Yisheng Pharmaceutical Co., Ltd. (SZSE:002566) As Shares Slide 25%